返回
T
Tomasz Bączek
medical university of gdansk
39H指数
366论文数
5.8K被引数
收录论文 164
发表时间
Comparative Mechanistic Insights and Therapeutic Potential of Pembrolizumab, Durvalumab, and Ipilimumab as Immune Checkpoint Inhibitors in the Targeted Management of Oral and Head and Neck Squamous Cell CarcinomaKawczak, P.; Feszak, I.J.; Bączek, T. 比较Pembrolizumab、Durvalumab和Ipilimumab作为免疫检查点抑制剂在靶向治疗口腔及头颈部鳞状细胞癌中的机制性见解与治疗潜力。Cancers 2025, 17, 2805. [Google Scholar] [CrossRef]
Cancers
IF4.4

